Cosmos Health Inc. (COSM)

Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million

Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue

Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline

Reviewing Cosmos Health (NASDAQ:COSM) & Community Health Systems (NYSE:CYH)

Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June

Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market

Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units

Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market

Cosmos Health: A Company Transformed — 2026 Year-to-Date

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

Cosmos Health Share Buyback Expands to 5.11 Million Shares; Continues Open Market Repurchases

Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases